Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.
about
Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndromeAntibodies to probe endogenous G protein-coupled receptor heteromer expression, regulation, and functionRifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) LigandsG Protein-Coupled Receptor Heteromers.Drug discovery approaches to irritable bowel syndrome.Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist.Eluxadoline (Viberzi): A Mu-Opioid Receptor Agonist for the Treatment Of Irritable Bowel Syndrome With Diarrhea.Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea.New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline.Two delta opioid receptor subtypes are functional in single ventral tegmental area neurons, and can interact with the mu opioid receptor.Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System.Antidiarrheal and Antioxidant Activities of Methanol Extract of Bryophyllum pinnatum Leaf Harvested from South-Eastern Nigeria in Mice.Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions
P2860
Q26743440-5305CE74-DE03-4E4A-8AE3-42C8ED60CA9BQ26992192-D4FCEDC3-BCD5-41D3-9285-DEB53B1340F8Q33466527-C70A91AB-2236-4CE1-8F10-E546D6478855Q35468805-ABF8727E-D0F2-424F-9CBE-EBFD5A29C350Q36635468-C3A90021-F73D-4A16-B395-D38AD5F7F5E1Q36947975-5AE4E9BD-30EF-4744-BDCE-10AD2E0172BDQ37489251-1EA31A6C-0313-470A-9EB4-B929F365371EQ38550878-CC25D6A3-5300-4DD8-B2FF-E33EE072CDD1Q38675489-1523B00B-0AA9-4FDD-B569-4AF67C2E0F1FQ38772302-217D3BD6-DA4A-4D36-81EB-C92995916A62Q38856699-EA259845-31CC-4B3B-B498-C8995BAC38CBQ39298126-71FD1957-86AE-48D0-8812-CE49A6D433CBQ39372153-0CA2F3B0-F06D-483C-8AB5-0CC9A1A1B72BQ41064891-239AFDD0-51C5-4DE0-9FD5-50491F651D02Q42184351-9B317AA9-D90C-4A5E-8D23-25D6EBD7C6F9Q43062026-002E2E3A-B258-4BA0-907E-FD7A2B420E27Q44346788-F538D4B9-7A79-4B14-8F1E-CCD5A30F4E4BQ55252194-2395B49D-54B9-4EC3-926A-5B1247641548Q55554959-5B82D988-B904-4AFD-95F3-50DC34F19EE8Q57818362-D0402C09-9884-4FD4-BD8A-A20721C21035
P2860
Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Molecular characterization of ...... ta opioid receptor heteromers.
@en
type
label
Molecular characterization of ...... ta opioid receptor heteromers.
@en
prefLabel
Molecular characterization of ...... ta opioid receptor heteromers.
@en
P2093
P2860
P1476
Molecular characterization of ...... ta opioid receptor heteromers.
@en
P2093
David Prohaska
Gail McIntyre
Ivone Gomes
Lakshmi A Devi
Leonard S Dove
Wakako Fujita
P2860
P304
P356
10.1016/J.BCP.2014.09.015
P407
P577
2014-09-28T00:00:00Z